Therapy with drugs containing the active ingredient LOMITAPIDE in patients with homozygous form of familial hypercholesterolemia: a statement of the committee of the Czech Society for Atherosclerosis


Authors: Vladimír Bláha 1;  Michal Vrablík 2;  Vladimír Soška 3;  Jan Piťha 4;  Renata Cífková 5;  Tomáš Freiberger 6;  David Karásek 7;  Pavel Kraml 8;  Hana Rosolová 9;  Tomáš Štulc 2;  Zuzana Urbanová Za Výbor Čsat 10
Authors‘ workplace: III. interní gerontometabolická klinika LF UK a FN Hradec Králové 1;  Klinika dětského a dorostového lékařství 1. LF UK a VFN v Praze 10;  III. interní klinika 1. LF UK a VFN v Praze 2;  Oddělení klinické biochemie, II. interní klinika LF MU a FN u sv. Anny v Brně 3;  Interní klinika 2. LF UK a FN Motol a Laboratoř pro výzkum aterosklerózy IKEM, Praha 4;  Centrum kardiovaskulární prevence 1. LF UK a Thomayerova nemocnice, Praha 5;  Centrum kardiovaskulární a transplantační chirurgie, Brno 6;  III. interní klinika – nefrologická, revmatologická a endokrinologická LF UP a FN Olomouc 7;  II. interní klinika 3. LF a FN Královské Vinohrady, Praha 8;  II. interní klinika LF UK a FN Plzeň 9
Published in: AtheroRev 2020; 5(2): 76-82
Category: Guidelines


Sources
  1. Vaclová M, Vrablík M. Novinky o familiární hypercholesterolemii pro kardiology. Kardiol Rev Int Med 2019; 21(2): 60–64.
  2. Thompson GR, Barbir M, Davies D et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010; 208(2): 317–321. Dostupné z DOI: <https://doi.org/10.1016/j.atherosclerosis.2009.06.010>.
  3. Cuchel M, Bruckert E, Ginsberg HN et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35(32): 2146–2157. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu274>.
  4. France M, Rees A, Datta D et al. [HEART UK Medical Scientific and Research Committee]. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis 2016; 255: 128–139. Dostupné z DOI: <https://doi.org/10.1016/j.atherosclerosis.2016.10.017>.
  5. Freiberger T, Vaclová M, Tichý L et al. Familiární hypercholesterolemie v České republice v roce 2016. Vnitř Lék 2016; 62(11): 924–928.
  6. Alonso R, Díaz-Díaz JL, Arrieta F et al. Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry. J Clin Lipidol 2016; 10(4): 953–961. Dostupné z DOI: <https://doi.org/10.1016/j.jacl.2016.04.006>.
  7. Sánchez-Hernández RM, Civeira F, Stef M et al. Homozygous Familial Hypercholesterolemia in Spain. Circ Cardiovasc Genet 2016; 9(6): 504–510. Dostupné z DOI: <https://doi.org/10.1161/CIRCGENETICS.116.001545>.
  8. LOJUXTA. SPC. European Medicines Agency (EMA). Dostupné z WWW: <https://www.ema.europa.eu/en/documents/product-information/lojuxta-epar-product-information_en.pdf>.
  9. Blom DJ, Averna MR, Meagher EA et al. Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients with Homozygous Familial Hypercholesterolemia. Circulation 2017; 136(3): 332–335. Dostupné z DOI: <https://doi.org/10.1161/CIRCULATIONAHA.117.028208>.
  10. Blom DJ, Cuchel M, Ager M et al. Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia. Orphanet J Rare Dis 2018; 13(1): 96. Dostupné z DOI: <https://doi.org/10.1186/s13023–018–0841–3>.
  11. Græsdal A, Bogsrud MP, Holven KB et al. Apheresis in homozygous familial hypercholesterolemia: The results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J Clin Lipidol 2012; 6(4): 331–339. Dostupné z DOI: <https://doi.org/10.1016/j.jacl.2012.03.004>.
  12. Kayikcioglu M, Tokgozoglu L, Yilmaz M et al. A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry). Atherosclerosis 2018; 270: 42–48. Dostupné z DOI: <https://doi.org/10.1016/j.atherosclerosis.2018.01.034>.
  13. D’Erasmo L, Cefalù AB, Noto D et al. Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical experience in Italy. Adv Ther 2017; 34(5): 1200–1210. Dostupné z DOI: <https://doi.org/10.1007/s12325–017–0531-x>.
  14. Kolovou G, Diakoumakou O, Kolovou V et al. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia. Eur J Prev Cardiol 2020; 27(2): 157–165. Dostupné z DOI: <https://doi.org/10.1177/2047487319870007>.
  15. Cuchel M, Meagher EA, du Toit Theron HE et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013; 381(9860): 40–46. Dostupné z DOI: <https://doi.org/10.1016/S0140–6736(12)61731–0>.
  16. A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH). Dostupné z WWW: <https://clinicaltrials.gov/ct2/show/NCT00730236>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adults

Article was published in

Athero Review

Issue 2

2020 Issue 2

Most read in this issue
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account